Biodexa Pharmaceuticals (BDRX) Other Accumulated Expenses (2014 - 2017)

Biodexa Pharmaceuticals has disclosed Other Accumulated Expenses across 4 years of filings, most recently posting $1.5 million for Q4 2017.

• In Q4 2017, Other Accumulated Expenses rose 4.5% year-over-year to $1.5 million; the TTM figure through Dec 2017 stood at $1.5 million (up 4.5% YoY), while the FY2017 annual figure was $1.5 million, down 7.08% from the prior year.
• Other Accumulated Expenses came in at $1.5 million for Q4 2017 at Biodexa Pharmaceuticals, up from $1.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q4 2017 to a low of $53112.2 in Q4 2015.
• Average Other Accumulated Expenses over 4 years is $824503.6, with a median of $865018.3 recorded in 2014.
• Year-over-year, Other Accumulated Expenses plunged 81.06% in 2015 and soared 2629.31% in 2016.
• Over 4 years, Other Accumulated Expenses stood at $280439.4 in 2014, then sank by 81.06% to $53112.2 in 2015, then soared by 2629.31% to $1.4 million in 2016, then climbed by 4.5% to $1.5 million in 2017.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.5 million in Q4 2017, $1.4 million in Q4 2016, and $53112.2 in Q4 2015.